# US 2021/0330815 A1 · Aav vector for treatment of friedreich's ataxia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0330815 A1
- Document ID: US20210330815A1
- Status: Published application
- Kind: A1
- Application number: 17/365,614
- Filed: 2021-07-01
- Published: 2021-10-28
- Earliest claimed: 2015-04-24
- Assignees: University of Florida Research Foundation, Inc.
- Applicants: University of Florida Research Foundation, Incorporated
- Inventors: Manuela Corti; Barry John Byrne
- Web page: https://patentgrep.com/patent/US20210330815A1

## CPC

- A61K 48/005: {characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered}
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 31/7088: Compounds having three or more nucleosides or nucleotides
- A61P 25/00: Drugs for disorders of the nervous system
- C12N 15/86: Viral vectors
- C12N 15/8645: {Adeno-associated virus}
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2800/22: Vectors comprising a coding region that has been codon optimised for expression in a respective host
- C12N 2840/105: enhancing translation
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

Provided herein are nucleic acids, recombinant adeno-associated viral particles, compositions and methods related to treating Friedreich's ataxia. In some examples, the nucleic acids, recombinant adeno-associated viral particles, compositions and methods involve us of a FXN coding sequence, a truncated FXN 3′ UTR, and a prompter.

## Claims

### Claim 1

A nucleic acid comprising an expression construct comprising a codon-optimized human frataxin (FXN) coding sequence and a truncated human FXN 3′ untranslated region (UTR) operably linked to a promoter, wherein the expression construct is flanked on each side by an inverted terminal repeat sequence.

### Claim 2

(canceled)

### Claim 3 (depends on 1)

The nucleic acid of claim 1, wherein the FXN coding sequence is at least 90% identical to a sequence within SEQ ID NO: 1 that encodes a 210 amino acid human FXN protein.

### Claim 4 (depends on 1)

The nucleic acid of claim 1, wherein the promoter comprises one or more of the following, or a fragment or variant thereof: a Desmin promoter, a chicken β-actin (CBA) promoter, or an endogenous human FXN promoter (hFXNPro).

### Claim at position 5

5-7. (canceled)

### Claim 8 (depends on 1)

The nucleic acid of claim 1, wherein the truncated human FXN 3′ UTR comprises the sequence of SEQ ID NO: 3.

### Claim 9

(canceled)

### Claim 10 (depends on 1)

The nucleic acid of claim 1, wherein the nucleic acid is a recombinant adeno-associated virus (rAAV) vector.

### Claim 11 (depends on 10)

The nucleic acid of claim 10, wherein the nucleic acid is a single-stranded or self-complementary rAAV nucleic acid vector.

### Claim 12 (depends on 10)

A recombinant adeno-associated virus (rAAV) particle comprising the nucleic acid of claim 10.

### Claim 13 (depends on 12)

The rAAV particle of claim 12, wherein the rAAV particle is an AAV9 particle.

### Claim 14 (depends on 12)

A composition comprising a plurality of the rAAV particle of claim 12.

### Claim 15 (depends on 14)

The composition of claim 14 further comprising a pharmaceutically acceptable carrier.

### Claim 16 (depends on 12)

A method of treating Friedreich's ataxia, the method comprising administering a therapeutically effective amount of the rAAV particle of claim 12 to a subject having Friedreich's ataxia.

### Claim 17 (depends on 16)

The method of claim 16, wherein the rAAV particle is administered via intravenous injection.

### Claim 18 (depends on 16)

The method of claim 16, wherein the rAAV particle is administered via intrathecal injection.

### Claim 19 (depends on 16)

The method of claim 16, wherein the rAAV particle is administered via intracisternal injection.

### Claim 20 (depends on 17)

The method of claim 17 further comprising administering the rAAV particle via intrathecal injection.

### Claim 21 (depends on 17)

The method of claim 17 further comprising administering the rAAV particle or via intracisternal injection.

### Claim 22 (depends on 20)

The method of claim 20, wherein the ratio of rAAV particle administered to the subject via intravenous injection to rAAV particle administered to the subject via intrathecal injection is 1:10.

### Claim 23 (depends on 21)

The method of claim 21, wherein the ratio of rAAV particle administered to the subject via intravenous injection to rAAV particle administered to the subject via intracisternal injection is 1:10.

### Claim 24 (depends on 1)

The nucleic acid of claim 1, wherein the truncated human FXN 3′ UTR is at least 100 nucleotides shorter than a wild-type FXN 3′ UTR.

### Claim 25 (depends on 24)

The nucleic acid of claim 24, wherein the truncated FXN 3′ UTR sequence has at least 85% sequence identity with the corresponding sequence in a wild-type FXN 3′ UTR.

### Claim 26 (depends on 1)

The nucleic acid of claim 1, wherein the truncated human FXN 3′ UTR is between 500 and 800 nucleotides shorter than a wild-type FXN 3′ UTR.
